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Ras is a key regulator of cell growth in all eukaryotic cells.
Genetic, biochemical, and molecular studies in Caenorhabditis
elegans, Drosophila, and mammalian cells have positioned Ras
centrally in signal transduction pathways that respond to di-
verse extracellular stimuli, including peptide growth factors,
cytokines, and hormones. The biological activity of Ras is con-
trolled by a regulated GDP/GTP cycle. Guanine nucleotide ex-
change factors (GEFs1; RasGRF1/2 and Sos1/2) promote the
formation of the active, GTP-bound form of Ras (1). GTPase-
activating proteins (GAPs; p120 GAP and NF1) accelerate the
intrinsic GTP hydrolytic activity of Ras to promote formation of
the inactive, GDP-bound form of Ras (1). Mutations in Ras at
amino acids 12, 13, or 61 make Ras insensitive to GAP action
and, hence, constitutively active in transforming mammalian
cells (2, 3). These activating mutations in Ras are prevalent in
a wide spectrum of human cancers. It has been estimated that
30% of all human tumors contain an activating mutation in
Ras. The frequency of Ras mutations varies depending on tu-
mor type, with the highest frequencies seen in lung, colon,
thyroid, and pancreatic carcinomas (3). The frequency of Ras
mutations is likely to be an underestimation of the contribution
of aberrant signaling through the Ras pathway to human ma-
lignancies because chronic up-regulation of the Ras pathway
can occur in the absence of mutations in Ras itself (4–6).
Ras Directly Binds Raf and Activates a Kinase
Cascade
Ras mediates its effects on cellular proliferation in part by
activation of a cascade of kinases: Raf (c-Raf-1, A-Raf, and
B-Raf), MEK (MAPK/ERK kinases 1 and 2), and ERK1/2 (7).
Upon activation, the ERKs phosphorylate cytoplasmic targets
(such as Rsk (8) and Mnk (9, 10)) and translocate to the nu-
cleus, where they stimulate the activity of various transcrip-
tion factors that include the Elk-1 transcription factor (Fig. 1).
Ras activates this kinase cascade by directly binding to Raf (11,
12). The binding of Ras to Raf requires active, GTP-bound Ras
and an intact effector domain. The recent observation that Ras
interacts with two distinct NH2-terminal regions of Raf-1 (RID/
RBS1, spanning residues 51–131 (13, 14) and Raf-CRD (14))
suggests that Ras promotes more than just membrane trans-
location of Raf and instead may also facilitate the subsequent
events that lead to Raf-1 activation. Other components that
contribute to Raf-1 activation include 14-3-3 proteins, phospho-
lipids, and serine/threonine and tyrosine kinases (15). There-
fore, the connection between Ras and Raf alone is not simply
linear and requires multicomplex formation to complete Raf
activation.
Ras Targets Multiple Effectors
Ras is likely to act through additional proteins besides Raf.
The earliest observations that Ras has multiple effector pro-
teins came from genetic studies in the budding yeast Saccha-
romyces cerevisiae and later the fission yeast Schizosaccharo-
myces pombe. Budding yeast devoid of Ras function were
inviable, but yeast lacking adenylyl cyclase, an effector of Ras
in this organism, were often capable of forming slow growing
microcolonies (16). This result suggested that Ras proteins in
S. cerevisiae have an essential function other than the activa-
tion of adenylyl cyclase. In S. pombe, Ras directly interacts
with two effectors: Byr2, a MAPK kinase kinase, and Scd1, a
GEF for the Rho family protein Cdc42 (17). Three additional
observations in mammalian cells indicated that the events
downstream of Ras are more complex than simply activating
the Raf kinase. First, activated Raf induces only a subset of the
events mediated by activated Ras. For example, activated Ras
activates three distinct MAPK cascades (ERK, JNK, p38),
whereas Raf causes direct activation only of ERK (18, 19).
Second, activated Raf is not sufficient to promote all functions
of Ras, such as the transformation of some epithelial cells (20).
Third, studies with Ras mutants that discriminate between
effectors suggest that multiple effector-mediated pathways are
important for establishing and maintaining the transformed
state (21, 48).
A plethora of candidate Ras effectors in addition to Raf have
been reported. These include p120 Ras GAP (22), GEFs for the
small GTPase Ral (RalGDS, RGL, RLF/RGL2) (23), AF6/Canoe
(24, 25), RIN1 (26), and phosphatidylinositol 3-kinase (PI3K)
(27). Although these candidate effectors comprise a very di-
verse collection of structurally and functionally distinct pro-
teins, they all show preferential affinity for active Ras-GTP.
Therefore, it is not surprising that residues corresponding to
the switch I (Ras residues 30–37) and II (residues 59–76),
which define the conformation differences between the GDP-
and GTP-bound Ras, are involved in effector recognition. Spe-
cifically, an intact core Ras effector domain (residues 32–40) is
essential for all effector interactions. Mutation of residues in
sequences flanking this region (spanning residues 25–45) show
differential impairment of effector interactions and provide
useful mutants to decipher the contribution of specific effectors
for Ras function (28). Thus, Ras residues important for effector
interaction are more extensive than originally believed. The
interaction of Ras with candidate effectors is often direct (in-
teraction is observed in vitro using proteins purified from bac-
teria). For some, the interaction with Ras is observed in vivo
upon co-immunoprecipitation, but these experiments are often
done under conditions in which the Ras target is overex-
pressed. To date, Raf is the only Ras target protein for which
genetic studies confirm its fundamental role in Ras signaling in
a normal cellular context. Nonetheless, the interaction of Ras
with at least some of these target proteins is likely to be critical
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for mediating the role of oncogenic Ras in malignant
transformation.
Multiple Effector Pathways Contribute to
Ras-mediated Transformation
What is the contribution of each of the known effector-medi-
ated pathways to malignant transformation? The current state
of affairs is depicted in Fig. 2. As described earlier, activation of
the Raf/ERK pathway, with its concomitant activation of tran-
scription factors, is essential for cell proliferation. The Ras
GTPase-activating protein, p120 GAP, in addition to negatively
regulating Ras function may impinge on the Rho family via its
association with p190, a GAP for Rho family members (29).
Activation of members of the Rho family of GTPases is likely to
contribute significantly to the Ras-transformed phenotype (re-
viewed in Ref. 30).
The family of GEFs for Ral have also been implicated as
target proteins for Ras (31, 32). A role for Ral in regulation of
phospholipase D and in actin cytoskeletal rearrangements (via
interaction with RalBP1) has been suggested (33, 34). In one
report, RalA has been reported to cooperate with Ras for trans-
formation (35), but others have not seen this cooperativity (36).
Perhaps the RalGDS targets other proteins in addition to Ral
that can influence the transformed phenotype. There is prece-
dence for multiple functions residing in GEFs; SOS facilitates
the exchange of nucleotides on Ras and couples Ras to Rac
through its Dbl and pleckstrin homology (PH) domains in a
PI3K-dependent manner (37).
RIN1 was identified in a genetic selection for mammalian
cDNAs that were capable of suppressing the phenotypes asso-
ciated with constitutive activation of the Ras pathway in S.
cerevisiae (38). RIN1 interacts directly with Ras in a GTP- and
effector domain-dependent fashion and localizes to the plasma
membrane (26). Subsequently, RIN1 was shown to interact
with Abl and Bcr/Abl in vitro and in vivo through a domain
distinct from the Ras binding domain (39, 40). Moreover, RIN1
can enhance the transforming activity of Bcr/Abl and rescue
several transformation-defective mutants of Bcr/Abl (40). The
aspects of Ras function mediated by RIN1 are still the subject
of investigation, but one possibility is that RIN1 coordinates
signals from Ras and Abl.
Biochemically, AF6/Canoe are candidate Ras effectors (25).
In addition, genetic studies in Drosophila have linked Canoe to
Ras in eye development (41). Canoe/AF6 have a GLG(F/D)HR
motif, a conserved sequence found in proteins that associate
with cellular junctions, so perhaps Canoe/AF6 coordinate sig-
naling events at the plasma membrane to remodeling of the
actin cytoskeleton.
Finally, activation of PI3K, via a direct interaction between
Ras and the catalytic subunit of the protein, is necessary for
actin cytoskeletal rearrangements associated with the trans-
formed phenotype (36). PI3K is a lipid kinase with specificity
for the 3-position of the inositol ring. Activation of PI3K by a
variety of extracellular stimuli leads to the accumulation of the
second messenger phosphatidylinositol 3,4,5-trisphosphate.
What are the downstream targets of this second messenger?
One target is the serine/threonine kinase Akt/PKB. Binding of
Akt/PKB via its PH domain to phosphatidylinositol 3,4,5-
trisphosphate localizes Akt/PKB to the plasma membrane and
leads to a partial activation of its kinase activity (42). Akt/PKB
activity is further increased by phosphorylation on 2 residues
by two different kinases, one of which, PDK1, is itself a lipid-
regulated kinase (43). The events downstream of Akt/PKB are
the subject of intense investigation in many laboratories. Akt/
PKB phosphorylates and inactivates the pro-apoptotic protein
BAD (44, 45) but is likely to have additional substrates. Other
targets of the products of PI3K include the PH domains of Vav
(46), SOS (37), and GRP1 (47).
One of the more elegant approaches to understanding the
contribution of each of the effector pathways to Ras-mediated
transformation has been the use of Ras effector mutants that
are impaired in binding a specific target (21, 36, 48, 49). For
example, studies with effector domain mutants have revealed a
bifurcation of the signaling pathways downstream of Ras lead-
ing to remodeling of the actin cytoskeleton and DNA synthesis.
RasV12C40, an activated mutant of Ras with an alteration of
tyrosine to cysteine at position 40 in the effector domain, is
unable to bind Raf. This mutant fails to activate the ERK
cascade and cannot activate a Ras-responsive reporter con-
struct, but it is capable of inducing membrane ruffling to the
same extent as an activated Ras with an intact effector domain
(49). These results suggest that stimulation of membrane ruf-
fling and activation of the ERK cascade are mediated by dis-
tinct Ras effector proteins. Subsequently, RasV12C40 was
shown to bind to and activate PI3K, suggesting that Ras-
induced morphological alterations may be mediated in part
through activation of PI3K (36). In addition to binding PI3K,
RasV12C40 will also interact with AF6 (48), and a role for AF6
in modulation of the actin cytoskeleton by RasV12C40 cannot
be excluded. Finally, the ability of this mutant to cause tumor-
igenic transformation demonstrates that Raf-independent
pathways alone are sufficient to promote Ras transformation.
Two additional approaches to dissect the contributions of
this surfeit of candidate effector proteins to Ras function have
been to overexpress or membrane-target a specific effector to
FIG. 1. Ras regulates a cascade of kinases. Ras is a GDP/GTP-
regulated binary switch that resides at the inner surface of the plasma
membrane and acts to relay extracellular ligand-stimulated signals to
cytoplasmic signaling cascades. A linear pathway where Ras functions
downstream of receptor tyrosine kinases (RTK) and upstream of a
cascade of serine/threonine kinases (Raf . MEK . ERK) provides a
complete link between the cell surface and the nucleus. Activated ERKs
can translocate into the nucleus to phosphorylate and activate tran-
scription factors, such as Elk-1. Activated ERKs also phosphorylate
substrates in the cytoplasm, including the Mnk kinase, and thus con-
tribute to translation initiation of mRNAs with structured 59-untrans-
lated regions.
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see if this mimics any aspect of Ras function. Targeting to the
plasma membrane is often achieved by adding the sequence
containing the CAAX box of Ras to the effector of interest.
Membrane targeting has been shown to cause constitutive ac-
tivation of Raf and PI3K. If membrane targeting of the candi-
date effector does not reproduce any aspect of Ras function, it
may be that the target protein under study is already consti-
tutively localized in this cellular compartment. Although Raf
and PI3K reside in the cytoplasm and become associated with
the plasma membrane upon receipt of stimulatory signal(s),
other Ras target proteins, such as adenylyl cyclase in yeast and
the RalGDS, are constitutively membrane localized. Mem-
brane-targeted RalGDS did not exhibit any transforming po-
tential.2 Finally, a powerful (but as yet not common) approach
to decipher the role of a Ras target protein is to determine
whether fibroblasts derived from mice deficient in a target
protein are impaired in transformation (for example, see Ref.
50).
Ras Mediates Life and Death Decisions by
Distinct Effector Pathways
One perplexing aspect of the Ras signaling pathway is that
Ras can promote both cell death and cell survival through
interactions with distinct effector proteins. Using Ras mutants,
Kauffmann-Zeh et al. (51) demonstrated that activation of Raf
by Ras promotes apoptosis in fibroblasts containing an induc-
ible c-Myc oncoprotein, whereas activation of PI3K by Ras
promotes cell survival. In this assay, oncogenic Ras enhanced
apoptosis. This result suggests that Ras has the potential to
trigger two seemingly contradictory biological outcomes: cell
death by activation of Raf and cell survival by activation of
PI3K. At least in this assay system, cell death (the Raf path-
way) is dominant over cell survival (the PI3K pathway). How
this seemingly discordant choice of cell death versus survival is
achieved is not known.
What is the contribution of each of these pathways to tumor
initiation and/or progression? Promotion of cell death by acti-
vation of Raf may be an important factor in limiting the expan-
sion of cells harboring Ras mutations, whereas promotion of
cell survival by activation of PI3K may contribute to tumor
expansion and metastases. It will be interesting to see if the
relative contributions of these antagonistic pathways can be
modulated by other signaling pathways and whether such mod-
ulation plays a role in tumor formation.
Activated Ras also promotes cell survival in epithelial cells
upon detachment from an extracellular matrix (52). This action
of Ras is mediated through activation of PI3K and Akt/PKB.
Given that the majority of human tumors are of epithelial cell
origin, a pharmacological intervention that could switch a Ras-
dependent survival signal into an apoptotic signal might be of
considerable value in the treatment of human malignancies.
Summary
The last 5 years have seen an impressive expansion in the
number of candidate Ras effectors. Much progress has been
made toward deciphering the aspects of Ras function mediated
by each of these proteins, and many studies, in particular those
with effector domain mutants, have convincingly demonstrated
that Ras must target at least three different pathways for
transformation. The corruption of the signaling pathways that
lie downstream of Ras is a recurring theme in the initiation
and/or progression of human malignancies. Pharmacological
interventions have directly impeded Ras function by interfer-
ing with its farnesylation and membrane targeting or have
blocked activation of components of the kinase cascade down-
stream of Ras (53). However, the function of Ras and its down-
stream kinase cascade is central to many cellular processes,
and this may limit the usefulness of these approaches. The
diversity of Ras target proteins and the necessity for activation
of multiple effector pathways for malignant transformation by
Ras open new directions for the design of additional therapeu-
tic interventions that may negate Ras transformation without
abolishing all of Ras function.
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